ClinicalTrials.gg
RecruitingNCT07085559Updated Jul 25, 2025

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

An Early Phase 1 interventional study of Metabolically Armed BCMA CAR-T cells. in Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) and AL Amyloidosis (AL), sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Anhui Provincial Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
4th of 19
36 · median 24
Started
2025
with 5 others
Phase 1
7 of 20
7 open now
Primary completion
2027-06
later than 11 of 17 live
Registered
14th of 20
by date
Lead sponsor
1 of 20
Anhui Provincial Hospital

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 11 of the 17 other live ones, and was the 14th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.

Read the detailed description

This is an open-label study. This study is indicated for relapsed or refractory Plasma Cell Neoplasms.The selections of dose levels and the number of subjects are based on clinical trials of similar products and the outcomes of our preliminary clinical studies.

  1. Main research objectives:

    To evaluate the safety and tolerability of metabolically armed BCMA CAR-T Cells in the treatment of r/r plasma cell neoplasms.

  2. Secondary research objectives:

(1)To evaluate the pharmacokinetic (PK) and pharmacodynamics (PD) characteristics of metabolically armed BCMA CAR-T cells after infusion.

(2) To evaluate tumor remission after infusion of metabolically armed BCMA CAR-T Cells.

03

Conditions studied

  • Multiple Myeloma (MM)
  • Plasma Cell Leukemia (PCL)
  • AL Amyloidosis (AL)

Browse trials for

Keywords

  • Meta10-BCMA
  • CAR-T Cells Therapy
  • r/r plasma cell neoplasms
04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

This study's planned enrollment of 36 is above the median of 27 across 53 interventional studies indexed under Leukemia, Plasma Cell.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

Anhui Provincial Hospital is the lead sponsor of 135 studies on the registry; 101 are open to participants now.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 to 75 years old, male or female. The subject or his/her guardian voluntarily signed the ;
  • Subjects with Plasma Cell Neoplasms(including Multiple Myeloma, Plasma Cell Leukemia, AL Amyloidosis)according to IMWG criteria and have had at least 3 (including chemotherapy based on proteasome inhibitors and immunomodulatory agents). Disease progression must be documented during or within 12 months following the most recent anti-myeloma treatment (for subject whose last-line treatment was CAR-T, disease progression was not limited to occurring within 12 months after treatment).
  • Evidence of cell membrane BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue.
  • The subjects were unable to receive hematopoietic stem cell transplantation treatment, or relapsed after autologous hematopoietic stem cell transplantation, and the researchers determined that treatment was needed.
  • performance score 0-2 (except for subjects with central nervous system invasion, which needs to be confirmed by the investigator).
  • Estimated ≥12 weeks.
  • Subjects should have adequate organ function:

    1. Complete blood count (CBC) test [the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection]: (ANC) ≥1×10\^9 /L; ≥70 g/L.; platelets ≥50×10\^9 /L; absolute lymphocyte count (ALC) ≥0.3×10\^9 /L;
    2. Liver function: (ALT) and aspartate aminotransferase (AST) ≤ 2.5× (ULN); total serum ≤ 1.5×ULN.
    3. Kidney function: Serum creatinine ≤2.5×upper limit of normal (ULN), or; rate (CrCl) calculated according to Cockcroft-Gault formula ≥ 60 ml/min.
    4. Electrolytes: Serum potassium ≥ 3.0 mmol/L; Serum calcium ≥ 2.0 mmol/L; Serum magnesium ≥ 0.5 mmol/L.
    5. Coagulation function: Fibrinogen ≥ 1.0 g/L; (APTT) ≤ ULN+10s, prothrombin time (PT) ≤ ULN+3s.
    6. Cardiac function: (LVEF) ≥ 50%.
  • The subjects must be willing to provide valid initial diagnostic evidence and undergo bone marrow examinations before and after treatment.
  • Women of childbearing age and all male patients must consent to use a effective for at least 12 months after Meta10-BCMA infusion and until two consecutive PCR tests show no more CAR T cells in vivo;
  • The subjects should have based on at least one of the following parameters:

    1. The proportion of primitive naive or monoclonal plasma cells ≥ 5% by bone marrow cytology, bone marrow histology or flow cytometry;
    2. Serum monoclonal protein (M-protein) level: M protein ≥10 g/L for IgG type, M protein ≥5g/L for IgA, IgD, IgM, and IgE type;
    3. Urine M protein level ≥200 mg/24 hours;
    4. Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
    5. There are measurable extramedullary plasmacytoma lesions.

Exclusion criteria

Exclusion Criteria:

  • Treatment with the following therapies within the specified period:

    1. Any hematopoietic stem cell transplant() within 2 months prior to the start of infusion of Meta10-BCMA, or any therapy due to after HSCT within the screening period;
    2. Any major surgery within 4 weeks prior to screening;
    3. Any radiotherapy 2 weeks prior to screening;
    4. Any intrathecal treatment within 1 week prior to the start of infusion of Meta10-BCMA;
    5. Any within 4 weeks prior to the start of infusion of Meta10-BCMA and/or plan to receive live vaccines after participation in the trial;
    6. Any clinical trial therapy within 4 weeks prior to the start of infusion of Meta10-BCMA, or ongoing participation in other clinical trials.
  • Following disease or surgical history:

    1. ≥ grade 2 arrhythmia according to 5.0 grade or > 450 ms (male), QTc> 470ms (female) (QTc is calculated using Fridericia correction formula QTc = QT / RR0.33) subjects with a history of Torsades de pointes ventricular tachycardia or congenital prolonged QT syndrome;
    2. Subjects with any of the following diseases within 12 months before the screening: including but not limited to unstable angina pectoris, myocardial infarction, congestive heart failure and severe arrhythmia, coronary artery bypass grafting or peripheral artery bypass grafting surgery, cerebrovascular events (including ), etc.;
    3. Uncontrollable and active infections during the screening period regarded by the investigators;
    4. Subjects infected with (HIV);
    5. Subjects with active (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 100 IU/ml);
    6. The virus (HCV) antibody is positive, and the peripheral blood HCV RNA is positive;
    7. Subjects with severe electrolyte disturbance regarded by the investigators;
    8. Subjects with a clear gastrointestinal bleeding tendency, including the following: active local ulcer lesions, and fecal occult blood (≥ ++); subjects with a history of melena and hematemesis within two months prior to screening; Subjects who may have a major gastrointestinal bleeding history;
    9. Subjects with a history of solid organ transplantation;
    10. Subjects with other acute, severe, or chronic medical or psychological conditions regarded by investigators as not suitable for enrollment;
    11. Pregnant or lactating women.
  • Prohibited treatment and/or medication:

    1. Ongoing therapy with other anti-tumor drugs, including traditional Chinese medicine;
    2. On-going therapy with drugs that extend the QT interval (including Class Ia and III antiarrhythmic drugs);
    3. Subjects who need to receive oxygen daily;
    4. Long-term use of (except for local inhalation).
  • Others:

    1. Subject with a history of psychotropic substance abuse who are unable to quit or have mental disorders;
    2. Subjects with concomitant diseases or comorbidities that could seriously endanger the safety of the patient or affect the completion of the trial as judged by the investigators;
    3. There are not enough unmobilized mononuclear cells available for collection for CAR-T cell production.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Administration of Metabolically Armed BCMA CAR-T cells.

    Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. The study will design metabolically armed BCMA CAR-T cells(Meta10-BCMA) with different structures. A dose of Meta10-BCMA CAR-T cells will be infused on day 0.

    Drug: Metabolically Armed BCMA CAR-T cells.

Interventions

  • DrugMetabolically Armed BCMA CAR-T cells.

    Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.

    Also known as: Meta10-BCMA

07

What researchers measure

Primary outcomes

  1. MTD

    Determine the Maximal Tolerable Dose(MTD)

    Time frame: MTD will be determined based on DLTs observed during the first 35 days of study treatment.

  2. Adverse events (AEs)

    Adverse events will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    Time frame: 1 year post Meta10-BCMA infusion

Secondary outcomes

  1. Cmax

    The maximum concentration (Cmax) of CAR-T cell expansion in peripheral blood

    Time frame: 1 year post Meta10-BCMA infusion

  2. Pharmacodynamics

    Concentration levels of CAR-T related serum cytokines such as CRP, IL-6, INF-γ at each time point.

    Time frame: Up to 28 days after infusion

  3. Objective response rate (ORR)

    According to the IMWG 2016 version, evaluate the overall tumor response rate (including sCR, CR, VGPR, PR) and the number of subjects in each dose group and all subjects at 1 month, 3 months, 6 months, 9 months and 12 months after CAR-T treatment.

    Time frame: 1 year post Meta10-BCMA infusion

  4. Overall survival (OS)

    OS is measured from the date of the infusion of Meta10-BCMA to the date of the subjects' death.

    Time frame: 1 year post Meta10-BCMA infusion

  5. Progression-free survival (PFS)

    The time from the start of Meta10-BCMA treatment for the subjects to the first disease progression or death for any reason.

    Time frame: 1 year post Meta10-BCMA infusion

  6. Tmax

    The time to reach the maximum concentration (Tmax)

    Time frame: 1 year post Meta10-BCMA infusion

  7. AUC0-28d

    The area under the curve AUC0-28d at 28 days.

    Time frame: 1 year post Meta10-BCMA infusion

  8. AUC0-90d

    The area under the curve AUC0-90d at 90 days.

    Time frame: 1 year post Meta10-BCMA infusion

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 25, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Oct 15, 2027
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07085559
Collaborators
Leman Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jun 23, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Jul 25, 2025

Study contacts

Xingbing Wang, PhD
Contact
wangxingbing@ustc.edu.cn
86+13856007984

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion